Results 131 to 140 of about 70,554 (222)

Immediate and delayed hypersensitivity to biologicals in children—A practical approach: An EAACI task force report

Pediatric Allergy and Immunology, Volume 37, Issue 4, April 2026.
Abstract In the era of precision medicine, biologicals demonstrate how therapies can be personalized and directed against new targets. This type of therapy includes different molecules such as growth factors, immune modulators, vaccines, and monoclonal antibodies (mAbs).
Francesca Mori, Marina Atanaskovic‐Markovic, Annick Barbaud, Sevim Bavbek, Jean‐Christoph Caubet, Leticia de las Vecillas, Mattia Giovannini, Ekaterina Khaleva, Marina Labella, Luis Moral, Carmen Riggioni, Vito Sabato, Sophia Tsabouri, Stefania Arasi   +13 more
wiley   +1 more source

Self‐Immolative Systems in Diagnostic and Therapeutic Applications

ChemMedChem, Volume 21, Issue 5, 13 March 2026.
Self‐Immolative Systems enable the precise, residue‐free release of active molecules, drugs, probes, or sensors, via cyclization or elimination, triggered by specific stimuli. Their versatility drives advances in drug delivery, diagnostics, nanotechnology, materials chemistry, and biosensing, offering chemists control over molecular activation and ...
Windbedema Prisca Ouédraogo, Thomas Cailly, Valérie Collot   +2 more
wiley   +1 more source

Evaluation of the modulating effect of epidermal growth factor receptor inhibitor cetuximab in carbon-tetrachloride induce hepatic fibrosis in rats

Biochemistry and Biophysics Reports
Liver fibrosis, developed in almost all chronic liver injuries. Epidermal growth factor receptors (EGFR) have been thought to contribute to cirrhosis and liver fibrosis.
Mirza Alimullah, Asif Ul Haque Shuvo, Ishrat Jahan, Iffat Nowshin Ismail, S.M. Mufidul Islam, Mahnaj Sultana, Mahmudur Rahman Saad, Sabbir Raihan, Ferdous Khan, Md. Ashraful Alam, Nusrat Subhan   +10 more
doaj   +1 more source

miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer

Cellular & Molecular Biology Letters
Background Cetuximab resistance severely restricts its effectiveness in the treatment of patients with metastatic colorectal cancer (CRC). Previous studies have predominantly focused on the genetic level, with scant attention to the nongenetic aspects ...
Shiyun Chen, Zhaoli Tan, Yanli Lin, Fang Pang, Xiaojie Wu, Xiang Li, Yumeng Cui, Weiling Man, Ying Li, Yanghua Li, Lu Han, Miaomiao Gou, Zhikuan Wang, Guanghai Dai, Youliang Wang   +14 more
doaj   +1 more source

Tumor-stroma interactions influence the response to PI3K targeted agents in preclinical models of colorectal cancer (CRC) [PDF]

, 2019
Introduction: One of the main obstacle to the successful development of therapeutic strategies remains the identification of biomarker underlying drug resistance. Recently, investigators have become more aware the role of the tumor microenvironment (TME)
Bazzichetto, Chiara
core  

Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors. [PDF]

Neoplasia
Almaraz-Postigo S, Redondo-Puente M, Pandiella A.   +2 more
europepmc   +1 more source

Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells. [PDF]

Cell Death Discov
Olmo-González D, Zhou M, Oliveira NG, Zhou F, Yan F, González J, València-Clua K, Molina-Vila MA, Bertrán-Alamillo J, Giménez-Capitán A, Codony-Servat J, Rosell R.   +11 more
europepmc   +1 more source

The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial. [PDF]

Cancer Res Commun
Weidhaas JB, Harris J, Gillison ML, Blakaj D, Krempl GA, Higgins K, Phan J, Dunlap NE, Mahamood ST, Dorth J, Caudell JJ, Desai AB, Galloway TJ, Pennington JD, Currey A, Lathrop J, Torres-Saavedra PA, Hayes DN, Yom SS, Le QT.   +19 more
europepmc   +1 more source

ERBITAG: Non-interventional study on the efficacy of cetuximab in first-line therapy in patients with RAS wild-type metastatic colorectal cancer. [PDF]

BMC Cancer
Sahm SW, Neumann UP, Zahn MO, Schwittay M, Maintz C, Goehler T, Rubanov O, Hering-Schubert C, Janssen J, Stenzel K, Reinke J, Overkamp F.   +11 more
europepmc   +1 more source

Effectiveness of primary tumor resection for survival after first-line cetuximab or bevacizumab in KRAS wild-type metastatic colorectal cancer treated with subsequent trifluridine/tipiracil or regorafenib. [PDF]

Ann Coloproctol
Chen YH, Wu CC, Su CC, Lee PT, Su YC.
europepmc   +1 more source